Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548.
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211.
Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17.
Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Cancer Ther 2004;3:261.
Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. J Proc Natl Acad Sci 2007;104:7391.
Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anti-Cancer Agents 2005;5:65.
Kuppens IELM. Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 2006;1:57-70.
Hadden MK, Blagg BSJ. Dimeric Approaches to Anti-Cancer Chemotherapeutics. Anticancer Agents Med Chem 2008;8(7): 807-816.
